ROIVANT SCIENCES LTD. Operating Lease, Right-of-Use Asset, Amortization Expense
ROIVANT SCIENCES LTD. (ROIV) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $1.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-06
- ROIVANT SCIENCES LTD. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $1.39M, a 28.26% decline year-over-year.
- ROIVANT SCIENCES LTD. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $1.86M, a 5.48% decline year-over-year.
- ROIVANT SCIENCES LTD. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $2.53M, a 47.69% increase year-over-year.
- ROIVANT SCIENCES LTD. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $1.94M, a 22.99% increase year-over-year.
- ROIVANT SCIENCES LTD. operating lease, right-of-use asset, amortization expense for fiscal 2026 was $8.28M, a 20.94% increase from fiscal 2025.
- ROIVANT SCIENCES LTD. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $6.84M, a 0.03% decline from fiscal 2024.
- ROIVANT SCIENCES LTD. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $6.84M, a 9.52% decline from fiscal 2023.
- ROIVANT SCIENCES LTD. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $7.57M, a 4.06% increase from fiscal 2022.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.39M 10-Q · filed 2026-08-06 | $3.26M derived: sum of 2 quarters · filed 2026-08-06 | $5.79M derived: sum of 3 quarters · filed 2026-08-06 | $7.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $4.39M derived: sum of 2 quarters · filed 2026-05-20 | $6.33M derived: sum of 3 quarters · filed 2026-05-20 | $8.28M 10-K · filed 2026-05-20 |
| 2025-12-31 | $2.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | $4.47M derived: sum of 2 quarters · filed 2026-02-06 | $6.41M 10-Q · filed 2026-02-06 | $8.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-09-30 | $1.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10 | $3.88M 10-Q · filed 2025-11-10 | $5.86M derived: sum of 3 quarters · filed 2026-08-06 | $7.57M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.94M 10-Q · filed 2026-08-06 | $3.92M derived: sum of 2 quarters · filed 2026-08-06 | $5.63M derived: sum of 3 quarters · filed 2026-08-06 | $7.21M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $3.68M derived: sum of 2 quarters · filed 2026-05-20 | $5.26M derived: sum of 3 quarters · filed 2026-05-20 | $6.84M 10-K · filed 2026-05-20 |
| 2024-12-31 | $1.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | $3.29M derived: sum of 2 quarters · filed 2026-02-06 | $4.87M 10-Q · filed 2026-02-06 | $6.67M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-09-30 | $1.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10 | $3.16M 10-Q · filed 2025-11-10 | $4.96M derived: sum of 3 quarters · filed 2026-05-20 | $6.69M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-06-30 | $1.58M 10-Q · filed 2025-08-11 | $3.38M derived: sum of 2 quarters · filed 2026-05-20 | $5.11M derived: sum of 3 quarters · filed 2026-05-20 | $6.81M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-03-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $3.53M derived: sum of 2 quarters · filed 2026-05-20 | $5.22M derived: sum of 3 quarters · filed 2026-05-20 | $6.84M 10-K · filed 2026-05-20 |
| 2023-12-31 | $1.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-10 | $3.43M derived: sum of 2 quarters · filed 2025-02-10 | $5.05M 10-Q · filed 2025-02-10 | $6.60M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-09-30 | $1.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-12 | $3.32M 10-Q · filed 2024-11-12 | $4.87M derived: sum of 3 quarters · filed 2025-05-29 | $6.69M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-06-30 | $1.62M 10-Q · filed 2024-08-09 | $3.18M derived: sum of 2 quarters · filed 2025-05-29 | $4.99M derived: sum of 3 quarters · filed 2025-05-29 | $7.18M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-03-31 | $1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-29 | $3.37M derived: sum of 2 quarters · filed 2025-05-29 | $5.56M derived: sum of 3 quarters · filed 2025-05-29 | $7.57M 10-K · filed 2025-05-29 |
| 2022-12-31 | $1.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-13 | $4.00M derived: sum of 2 quarters · filed 2024-02-13 | $6.01M 10-Q · filed 2024-02-13 | $7.88M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-09-30 | $2.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-13 | $4.19M 10-Q · filed 2023-11-13 | $6.06M derived: sum of 3 quarters · filed 2023-11-13 | $7.80M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $2.00M 10-Q · filed 2023-08-14 | $3.87M derived: sum of 2 quarters · filed 2023-08-14 | $5.61M derived: sum of 3 quarters · filed 2023-08-14 | |
| 2022-03-31 | $1.87M derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-28 | $3.61M derived: sum of 2 quarters · filed 2023-06-28 | $7.27M 10-K · filed 2023-06-28 | |
| 2021-12-31 | $1.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-13 | $5.40M 10-Q · filed 2023-02-13 | ||
| 2021-09-30 | $3.66M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |